Author

A Pérez

Observed names: A Perez, A. Perez, A. Pérez, Alma D Hernández Pérez, Antonio Cueva Pérez

Institutions: Universidad Autónoma de Guadalajara, Instituto Nacional de Rehabilitación

Observed institutions: Universidad Autónoma de Guadalajara, University of California, San Francisco, University of California San Francisco Medical Center, Instituto Nacional de Rehabilitación, Memorial Regional Hospital, Complejo Asistencial Universitario de Palencia

ORCID: 0009-0004-5018-6875

Observed ORCID: 0009-0004-5018-6875

OpenAlex ID: A5112464818

Neurocognitive Side Effects Thwart Transition to Tezacaftor/Ivacaftor CFTR Modulator Therapy in Patients with F508del Homozygous Cystic Fibrosis

2019 · A. Perez, I.-S.V. Jue, et al. · 4

Patient-Tailored 3D Anatomical Modeling for Abdominal Reconstruction: Innovations, Surgical Impact, and Global Perspectives

2025 · Rogelio Alejandro Flores Arquieta, Rodrigo Martínez Rivera, et al. · IECCMEXICO

Extraskeletal Myxoid Chondrosarcoma With Rhabdoid Features in a Pediatric Patient

2025 · Juan J Andrade Rojas, Maria J Lizardo, et al. · Cureus

548: Evaluation of elexacaftor/tezacaftor/ivacaftor on pulmonary function in cystic fibrosis patients

2021 · A. Hamad, D. Hiner, et al. · Journal of Cystic Fibrosis

Is an early diagnosis of pancreatic cancer possible?

2015 · K. De Jesús, A. Pérez, et al. · Pancreatology

A multi-center phase II study of three doses of TAS-108 in postmenopausal women with advanced breast carcinoma following first or second line endocrine therapy.

2009 · A Buzdar, E Tan-Chiu, et al. · Cancer Research

Works count: 6

Citation count: 4

H-index: 1

I10-index: